3. anosia
TRIMESTRAL EDITION OF
THE HELLENIC SOCIETY OF IMMUNOLOGY
ISSN 1790-6490 VOLUME 3 ñ NUMBER 1-2
HELLENIC
SOCIETY OF
IMMUNOLOGY
Meandrou 23, 115 28 Athens |
Tel. + 30 210 7211845 | F·¯: + 30 210 7215082 |
E-mail: helsocimmun@yahoo.com |
contents
http: //mednet.gr/hsi
BOARD OF H.S.I.
President : P. Boura
Vice President : Ch. Nikolaou Etiopathogenetic mechanisms in Adamantiades-Behçet disease
General Secretary: F. Palioyianni
Specific Secretary : A. Tsiroyianni
Ph. Kaklamanis, E. Kaklamani .............................................................................................. 7
Treasurer : O. Moraloglou-Benetou
Members : Ch. Antzou-Agouridaki
Chronic hepatitis II – Chronic Hepatitis C
Th. Keramitsoglou E. Gigi, M. Raptopoulou-Gigi ............................................................................................... 17
EDITORIAL BOARD
Editor in Chief : P. Boura The complement in renal vascular diseases
Co-editors K. Paletas .................................................................................................................................. 35
Ch. Nikolaou
F. Palioyianni Ageing and the immune system
A. Tsiroyianni P. Skendros .............................................................................................................................. 40
O. Moraloglou-Benetou
Ch. Antzou-Agouridaki Genomics: a major challenge for the future of immunology
Th. Keramitsoglou
ADVISORY COMMITTEE
A. Kalogeridis ........................................................................................................................... 44
Board of Presidents of H.S.I.
† M. Pavlatou
Immunophenotyping study of alveolar cells in patients with
I. Ekonomidou connective tissue diseases and lung involvement
E. Kaklamani D. Papakosta, K. Manika, G. Kiriazis, A. Garifallos, Th. Kontakiotis,
A. Stavropoulou-Gioka
M. Varla-Leftherioti Th. Polizoni, P. Argiropoulou, D. Gioulekas, D. Bouros, D. Patakas ........................ 65
Z. Polymenidis
Ch. Papasteriadi Retroviruses in immunopathogenesis of Graves’ disease
M. Daniilidis G. Tsirakidis, M. Daniilidis, G. Kokaraki, Z. Polimenidis, N. Karadani,
G. Kiriazis Ph. Harsoulis ............................................................................................................................ 73
Professors of Immunology
M. Raptopoulou-Gigi T lymphocyte interleukin-2 receptor expression in patients with
F. Kanakoudi-Tsakalidou
P. Boura
idiopathic dilated cardiomyopathy: the effect of human cardiac
Editors myosin
A. Manthos J. Efthimiadis, P. Skendros, A. Sarantopoulos, P. Boura .............................................. 81
A. Germenis
G. Vergoulas The effect of Gram (–) and Gram (+) toxins on monocytes
EDITORIAL ASSISTANT COMMITTEE and endothelial cells
A. Sarantopoulos
P. Skendros J. Kiriakopoulou, L. Reynolds, E. Ioannidou, S. Haralambidou, J. Klonizakis ......... 89
K. Tselios
Estrogen receptor · (ER·) regulates the expression of Hepatic
SUBMISSION OF ARTICLES-SUBSCRIPTIONS
anosia Nuclear Factor 3· (HNF3·) in breast cancer
P. Boura, editor-in-chief C. Karadedou, M. Daniilidis, K. Giannoulis, E. Giannoulis .......................................... 97
Clinical Immunology Unit, 2nd Medical Clinic, Hippokratio
Gen. Hospital of Thessaloniki. |49 Konstantinoupoleos Str.
546 42 Thessaloniki, Greece
TËÏ. +30 2310 892239 & +30 2310 992810
e-mail: anosia@universitystudiopress.gr
Annual subscription € 30,00 Cover Figure: The intracellular transduction pathway. The same extracellular stimuli activate different
biological programs, offering the genetic advantage in certain members of a population. Manipulation of the
PUBLISHER
check points represents a potent therapeutic target.
UNIVERSITY STUDIO PRESS
A. Kalogeridis. Genomics – Proteomics – Cytomics: Prospective applications in Immunology: Anosia 2002;
Leonidas A. Michalis
Armenopoulou 32, 546 35 Thessaloniki Suppl: 107-115.
Tel. 2310 209637, 2310 209837, Fax 2310 216647
E-mail: info@universitystudiopress.gr
11. 14 ∞ÈÙÈÔ·ıÔÁÂÓÂÙÈÎÔ› Ì˯·ÓÈÛÌÔ› ÛÙË ÓfiÛÔ ∞‰·Ì·ÓÙÈ¿‰Ë-Behçet
matory conditions. What is a name. Clin Exp Rheumatol Lisbon 19-23 September 2006 (abstract A7).
2005; 23: S1-S2. 29. Direskeneli H, Eksioglu – Demiralp E, Yavuz S et al. T cell
12. Papoutsis NG, Abdel-Naser MB, Altenburg A, et al. responses to 60/65 K Da heat shock protein derived
Behcet’s disease and other autoinflammatory conditions. peptides in Turkish patients with Behcet’s disease. J
Clin Exp Rheumatol 2006; 24(5) Suppl 42: 125. Rheumatol 2000; 27: 708-13.
13. Cakir N, Dervis E, Benian O, et al. Prevalence of Behcet’s 30. Ergun T, Ince V, Eksiolgu- Demiralp E, et al. HSP 60 ex-
disease in rural Western Turkey: A preliminary report. pression in mucocutaneous lesions of Behcet’s disease. J
Clin Exp Rheumatol 2004; 22: (suppl. 34) 53-5. Am Acad Dermatol 2001; 45: 904-9.
14. Ohno S, Ohguchi M, Hirose S, et al. Close association of 31. Pervin K, Childerstone A, Shinnich T, et al. T cell epitope
HLA-BW51 with Behcet’s disease Arch Ophthalmol expression of mycobacterial and homologous human 65
1982; 100: 1455-8. KD heat shock protein peptides in short protein cell lines
15. Hirohata T, Kuratsune M, Nomura A, et al. Prevalence of from patients with Behcet’s disease. In Immunology
Behcet’s syndrome in Hawaii with particular reference to 1993; 151: 2273-82.
the comparison of the Japanese to Hawaii and Japan. 32. Direskeneli H, Saruhan – Direskeneli G. The role of heat
Hawaii Med J 1975; 34: 244-6. shock proteins in Behcet’s disease. Clin Exp Rheumatol
16. Aksu K, Kabasakal Y, Sayiner et al. Prevalence of hepatitis 2003; 21 (suppl. 30): S44-S48.
A, B, C and E viruses in Behcet’s disease. Rheumatology 33. Keneko S, Suzuki N, Yamashita N, et al. Characterization
1999; 38: 1279-81. of T cells specific for an epitope of human 60 KD heat
17. Cantini F, Emmi L, Niccoli L, et al. Lack of association bet- shock protein (hsp) in patients with Behcet’s disease in
ween chronic hepatitis C virus infection and Behcet’s Japan. Clin Exp Immunol 1997; 108: 204-11.
disease. Clin Exp Rheumatol 1997; 15: 338-9. 34. Al-Mutawa SA, Hegab SM. Behcet’s disease. Clin Exp Med
18. Sohn S, Bang D, Lee E-S, et al. Experimental studies on the 2004; 4: 103-31.
antiviral agent famciclovir in Behcet’s disease symptoms 35. Sobel JD, Haim S, Obedeanu N, et al. Polymorphonuclear
in ICR mice. Br J Dermatol 2001; 145: 799-804. leucocyte function in Behcet’s disease. J Clin Path 1977;
19. Kiraz S, Osturk MA, Ertenli I, et al. Parvovirus B19 infection 30: 250-3.
in Behcet’s disease. Ann Rheum Dis 2001; 60: 814-5. 36. James WD, Walter J R, Smith MJH. Abnormal polymor-
20. Marshall SE. Behcet’s disease. Best Pract Res Clin Rhe- phonuclear leucocytes chemotaxis in Behcet’s syndro-
umatol 2004; 18: 291-311. me, Ann Rheum Dis 1979; 38: 219-21.
21. Krause I, Monselise Y, Milo G, et al. Anti-saccharomyces 37. Gul A, Esin S, Dilsen N, et al. Immunohistology of skin
cerevisae antibodies- A novel serologic marker for pathergy reaction in Behcet’s disease. Br J Dermatol
Behcet’s disease. Clin Exp Rheuma 2002; 20 (suppl. 26): 1995; 132: 901-7.
S21-S24. 38. Carletto A, Facor ML, Biasi D, et al. Changes of neutrophil
22. Monselise A, Weinberger A, Monselise Y, et al. Anti-sac- migration without modification of in vivo metabolism
charomyces cerevisae antibodies in Behcet’s disease – a and adhesion in Behcet’s disease. J Rheumatol 1977; 24:
family study. Clin Exp Rheumatol 2006; 24 (suppl. 42); 1332-6.
S87-S90. 39. Takeno M, Kariyone Al, Yamishiro N, et al. Excessive fun-
23. Ayaslioglu E, Duzgun N, Ekkek E, et al. Evidence of chro- ction of peripheral blood neutrophils from patients with
nic Chlamydia pneumonia infection in patients with Behcet’s disease and from HLA-B51 transgenic mice.
Behcet’s disease. Scan J Infect Dis 2004; 36: 428-30. Arthritis Rheum 1995; 38: 426-33.
24. Zouboulis CC, Turnbull JR, Muhlredt PF. High seropre- 40. Sakane T. New perspective on Behcet’s disease. Intern Rev
valence of anti-mycoplasma Fermentans antibodies in Immunol 1997; 14: 89-96.
patients with malignant aphthosis – J Invest Rheumatol 41. Zouboulis CC, May T. Pathogenesis of Adamantiades –
2003; 121: 211-2. Behcet’s disease In: Adamantiades – Behcet’s disease.
25. Calguneri M, Kiraz S, Ertenli I, et al. The effect of pro- Advances in Exp Med and Biol 2003; 528: 161.
phylactic penicillin treatment on the course of arthritis 42. Haznedaroglou S, Karaaslan Y, Buyukasik Y, et al. Selection
episodes in patients with Behcet’s diseases. A adhesions molecules in Behcet’s disease. Ann Rheum Dis
randomized Clinical Trial. Arthritis Rheum. 1996; 39: 2000; 59: 61-3.
2062-2065. 43. Onder M, Gurer MA. The multiple faces of Behcet’s di-
26. Lehner Th. The role of heat shock protein, microbial and sease and its aetiological factors. J Eur Acad Dermatol
autoimmune agents in the aetiology of Behcet’s disease. Venereol 2000; 15: 126-36.
Intern Rev Immunol 1997; 14: 21-32. 44. Sahin S (Ozgun), Laurence R, Direskeneli H, et al. Mono-
27. Hirohata S, Oka H, Mizushima Y. Streptococcal-related cyte activity in Behcet’s disease. Br J Rheumatol 1996; 35:
antigens stimulate production of IL-6 and interferon –Á 424-9.
by T cells from patients with Behcet’s disease. Cell 45. Alpsoy E, Kodelja V, Gaerdt S, et al. Serum of patients with
Immunol 1992; 140: 410-9. Behcet’s disease classical (pro-inflammatory) activation
28. Kaneco F, Oyama N, Watanabe K, et al. Behcet’s disease of human macrophages in vitro. Dermatology 2003; 206:
is an inflammatory disorder by oral streptococcal al- 225-32.
lergy?12th International Conference on Behcet’s Disease. 46. Fortune F, Walker J, Lehner T. The expression of Á‰ T cell
12. º. ∫·ÎÏ·Ì¿Ó˘ Î·È Û˘Ó. 15
receptor and the prevalence of primed, activated and 63. Raziuddin S, Al-Dalaan A, Bahabri S et al. Divergent cytokine
IgA-bound T cells in Behcet’s syndrome. Clin Exp production profile in Behcet’s disease. Altered Th1/Th2
Immunol 1990; 82: 326-32. cell cytokine pattern J Rhematol 1998; 25: 329-33.
47. Eksioglu – Demiralp E, Kibaroglu A, Direskeneli H, et al. 64. Sugi – Ikai N, Nakazawa M, Nakamura S, et al. Increased
Phenotypic characteristics of B cells in Behcet’s disease: frequencies of interleukin-2 and interferon –Á- producing
Increased activity in B cell subsets. J Rheumatol 1999; 26: T cells in patients with active Behcet’s disease. Invest
826-32. Ophthalmol Visc Sci 1998; 39: 996-1104.
48. Freydotter J, Lau S-H, Fortune F. Á‰ Δ cells in Behcet’s di- 65. Aridogan B C, Yildirin M, Boysal V, et al. Serum level of IL-
sease (BD) and recurrent aphthous stomatitis (RAS). 4, IL-10, IL-12, IL-13 and IFN-gamma in Behcet’s disease.
Clin Exp Immunol 1999; 118: 451-7. J Dermatol 2003; 30: 602-7.
49. Suzuki Y, Hoshi K, Matsuda T, et al. Increased peripheral 66. Mantas C, Direskeneli H, Eksioglu – Dermiralp E, et al.
blood Á‰+cells and natural killer cells in Behcet’s disease. Serum levels of Th2 cytokines IL-4 and IL-10 in Behcet’s
J Rheumatol 1992; 19: 588-92. disease. J Rheumatol. 1992; 26: 510-2.
50. Esin S, Gul A, Hodara V, et al. Peripheral blood T cell 67. Al-Dalaan A, Al-Sedairy S, Al-Balaa S, et al. Enhanced
expansions in patients with Behcet’s disease. Clin Exp Interleukin 8 secretion in circulation of patients with
Immunol 1997; 107: 520-7. Behcet’s disease. J Rheumatol 1995; 22: 904-7.
51. Yamashita N, Kaneoka H, Kaneko S, et al. Role of Á‰ T 68. Hirohata S, Takeuchi A, Miyamoto T. Elevated levels of
lymphocytes in the development of Behcet’s disease. interleukin 6 in cerebrospinal fluid from patients with
Clin Exp Immunol 1997; 107: 241-7. neuro Behcet’s syndrome. In O’ Duffy JD, Kokmen E
52. Frassanito M A, Dammacco R, Cafforio P, et al. The pola- (eds) Behcet’s disease: basic and clinical aspects. Marcel
rization of the immune response in Behcet’s disease. A Dekker, 1991: 369-76.
putative pathogenetic role of interleukin -12. Arthritis 69. Itoh R, Takenaka T, Okitsu-Negishi S, et al. Interleukin 8 in
Rheum 1999; 42: 1967-74. Behcet’s disease. J Dermatol 1994; 21: 397-404.
53. Hamzaoui K, Hamzaoui A, Houman H. CD4+ CD25+ 70. Wang LM, Kitteringham N, Mineshita S, et al. The demon-
regulatory T cells in patients with Behcet’s disease. Clin stration of serum interleukin -8 and superoxide
Exp Rheumatol 2006; 24 (suppl. 42): S71-S78. dismutase in Adamadiades – Behcet’s disease. Arch
54. Eksioglu–Demiralp E, Direskeneli H, Ergun T, et al. In- Dermatol Res 1997; 289: 444-7.
creased CD4+ CD16+ and CD4+ CD56+ T cell sub- 71. Guz-Toy G, Lenk N, Yalcin N, et al. Serum interleukin -8
sets in Behcet’s disease. Rheumatol Int 1999; 19: 23-6. as a serogical marker of activity in Behcet’s disease. Int J
Dermatology 2005; 44: 657-60.
55. Hamzaoui K, Ayed K, Hamza M, et al. Natural killer cells in
Behcet’s disease. Clin Exp Immunol 1988; 71: 126-31. 72. Turan B, Gallati H, Erdi H, et al. Systemic levels of the T
cell regulatory cytokines IL-10 and IL-12 in Behcet’s
56. Kaneko F, Takahashi Y, Muramatsu R, et al. Natural killer
disease; soluble TNFR-75 as a biological marker of
cells number and function in peripheral lymphoid cells in
disease activity. J Rheumatol 1997; 24: 128-32.
Behcet’s disease. Br J Dermatol 1985; 113: 313-8.
73. Suzuki Kurokawa M, Suzuki N. Behcet’s disease. Clin Exp
57. Kibaroglu A, Eksioglu-Demiralp E, Akoglu T, et al. T and NK
Med 2004; 3: 10-20.
cell subset changes with microbial extracts and human
HSP 60- derived peptides in Behcet’s disease. Clin Exp 74. Ohno S, Kato F, Matsuda H, et al. Studies on spontaneous
Rheumatol 2004; 22 (suppl. 34): S59-S63. production of gamma – interferon in Behcet’s disease.
Opthalmologica 1982; 185: 187-92.
58. Sayinalp N, Ozcebe O I, Ordemir O, et al. Cytokines in
Behcet’s disease J Rheumatol 1996; 23: 321-2. 75. Gul A. Behcet’s disease: An update on the pathogenesis.
Clin Exp Rheumatol 2001; 19 (suppl. 24) S6-S12.
59. Mege J-L, Dilesen N, Sanguedolce V, et al. Overproduction
of monocyte derived tumor necrosis factor a, interleukin 76. Vaiopoulos G, Hatzinikolaou P, P. Tsiroyanni A, et al. An-
(IL) 6, IL-8 and increased neutrophil superoxide tineutrophil cytoplasmic antibodies in Adamantiades –
generation in Behcet’s disease. A comparative study with Behcet’s disease. Br J Rheumatol 1994; 33: 406-7.
familial mediterranean fever and healthy subjects. J 77. Hmida Ben M, Hachicha J, Kaddour N, et al. ANCA in
Rheumatol 1993; 20: 1544-9. Behcet’s disease. Nephrol Dial Transplant 1997; 12:
60. Zouboulis CC, Katsantonis J, Ketteler R, et al. Adaman- 2465-6.
tiades – Behcet’s disease: interleukin -8 is increased in 78. Pereira R-M.R, Gonvalves CR, Bueno C. Anticardiolipin
serum of patients with active oral and neurological ma- antibodies in Behcet’s syndrome: A predictor of a more
nifestations and is secreted by small vessel endothelial severe disease. Clin Rheumatol 1989; 8: 289-91.
cells. Arch Dermatol Res 2000; 292: 279-84. 79. Zouboulis CC, Buttner P, Tebbe B, et al. Anticardiolipin
61. AKaglu T, Direskeneli H, Yazici H, et al. TNF, soluble IL-2 antibodies in Adamantiades – Behcet’s disease. Br J
R and soluble CD-8 in Behcet’s disease. J Rheumatol Dermatol 1993; 128: 281-4.
1990; 17: 1107-8. 80. Tokay S, Diseskeneli H, Yardakul S, et al. Anticardiolipin
62. Evereklioglu C, Hamdi Er, Turkoz Y, et al. Current levels of antibodies in Behcet’s disease: a reassessment. Rhe-
TNF-a, SIL-2R, IL-6 and IL-8 are increased and associated umatology 2001; 40: 192-5.
with elevated lipid peroxidation in patients with Behcet’s 81. Aydintup AO, Tokgoz G, D’Cruz PP, et al. Antibodies to
disease. Mediat Inflam 2002; 11: 87-93. endothelial cells in patients with Behcet’s disease. Clin
13. 16 ∞ÈÙÈÔ·ıÔÁÂÓÂÙÈÎÔ› Ì˯·ÓÈÛÌÔ› ÛÙË ÓfiÛÔ ∞‰·Ì·ÓÙÈ¿‰Ë-Behçet
Immunol Immunopathol 1993; 67: 157-62. 94. Zervas J, Vaiopoulos G, Sakellaropoulos N, et al. HLA
82. Direskeneli H, Keser G, D’kruz D, et al. Antiendothelial cell antigens and Adamantiades – Behcet’s disease (A-BD) in
antibodies, endothelial proliferation and von Willebrand Greeks. Clin Exp Rheumatol 1988; 6: 277-80.
factor antigen in Behcet’s disease. Clin Rheumatol 1995; 95. Mizuki N, Yabuki K, Ota M, et al. Analysis of microsatellite
14: 55-61. polymorphism around the HLA – B locus in Iranian
83. Dinc A, Takafuta T, Jiang D, et al. Antiendothelial cell patients with Behcet’s disease. Tissue Antigens 2002; 60:
antibodies in Behcet’s disease. Clin Exp Rheumatol 2003; 396-9.
21 (suppl. 30): S27-S30. 96. Yabuki K, Mizuki N, Ota M, et al. Association of MICA
84. Mahesh SP, Li Z, Buggoge R, et al. Alpha tropomyosin as a gene and HLA – B*5101 with Behcet’s disease in
self antigen in patients with Behcet’ disease. Clin Exp Greece. Invest Ophthalm Vis Sci 1999; 40: 1921-6.
Immunol 2005; 140: 368-75. 97. Inaba G. Clinical features of neuro-Behcet’s syndrome: In
85. Mor F, Weinberger A, Cohen IR. Identification of alpha – Lehner, Barnes CG, eds. Recent advances in Behcet’s
tropomyosin as a target self-antigen in Behcet’s syn- disease. London: Royal society of Medicine Services
drome. Eur J Immunol 2002; 32: 356-65. 1986; 235-46.
86. Ozaran K, Durgun N, Tutkak H, et al. Fibronectin and cir- 98. Gul A, Uyar A, Inanc M, et al. Lack of association of HLA-
culating immune complexes in Behcet’s disease. Rhe- B*51 with a severe disease course in Behcet’s disease.
umatol Int 1996; 15: 221-4.
Rheumatology 2001; 40: 668-72.
87. Gupta RC, O Duffy JD, MC Guggie FC. Circulating immu-
99. Koumantaki Y, Stavropoulos C, Spyropoulou M, et al.
ne complexes in active Behcet’s disease. Arthritis Rheum
HLA- B*5101 in Greek patients with Behcet’s disease.
1977; 30: 250-3.
Human Immunology 1998; 59: 250-5.
88. Kevinsky RJ, Lehner T. Circulating immune complex in the
recurrent oral ulcerations and Behcet’s syndrome. Clin 100. Zouboulis CC, Buttner P, Djawari D, et al. HLA-Class 1
Exp Immunol 1978; 32: 193-8. antigens in German patients with Adamantiades Behcet’s
disease and correlation with clinical manifestations. In:
89. Kaya TI, Dur H, Tursen V, et al. Association of class I HLA
Behcet’s disease. Godeau P and Wechsler B (edrs).
antigens with the clinical manifestations of Turkish
Elsever Science Publ 1993; 44: 81-5.
patients with Behcet’s disease. Clin Exp Dermatol 2002;
27: 498-501. 101. Marin ML, Savioli CR, Yamamito JH, et al. MICA polymor-
90. Krause I, Mader R, Sulkes J, et al. Behcet’s disease in Israel: phism in a sample of the San Paolo population, Brasil.
the influence of ethnic origin on disease expression and Eun J Immunogenetics 2004; 31: 63-71.
severity. J Rheumatol 2001; 28: 1033-6. 102. Sanz L, Gonzalez – Escribano F, Pablo R, et al. HLA-CW
91. Kotter I, Gunaydin I, Stubiger N, et al. Comparative analy- 1602 a new susceptibility marker of Behcet’s disease in
sis of the association of HLA B 51 subalelles with BD in Southern Spain. Tissue Antigens 1998; 51: 111-4.
patients of German and Turkish origin. Tissue Antigens 103. Molinari N, Kone-Paut I, Manna R, et al. Identification of
2001; 58: 166-70. an autosomal recessive mode of inheritance in paediatric
92. Ohno S, Nakayama E, Sigiura S, et al. Specific histocom- Behcet’s families by segregation analysis. Am J Med
patibility antigens associated with Behcet’s disease. Am J Genet A 2003; 122: 115-8.
Ophthalmol 1975; 80: 636-41.
93. Mizuki N, Ota M, Katsuyama Y, et al. HLA class 1 geno-
∞ÏÏËÏÔÁÚ·Ê›·:
typing including HLA-B*51 allele typing in the Iranian
patients with Behcet’s disease. Tissue Antigens 2001; 57: º. ∫·ÎÏ·Ì¿Ó˘
457-62. virginia@hol.gr